Jolanta Dyniewicz

Dr. Jolanta Dyniewicz

Department of Neuropeptides, Mossakowski Medical Research Institute Polish Academy of Sciences, Pawińskiego 5, 02-106 Warsaw, Poland
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KGKarel Guillemyn
Karel Guillemyn
JSJoanna Starnowska
Joanna Starnowska
CLCamille Lagard
Camille Lagard
JDJolanta Dyniewicz
Jolanta Dyniewicz
EREwelina Rojewska
Ewelina Rojewska
Steven  BalletSteven Ballet
Steven Ballet

1 March 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KGKarel Guillemyn
Karel Guillemyn
Patrycja KleczkowskaPatrycja Kleczkowska
Patrycja Kleczkowska
ALAnna Lesniak
Anna Lesniak
JDJolanta Dyniewicz
Jolanta Dyniewicz
OPOlivier Van der Poorten
Olivier Van der Poorten
Steven  BalletSteven Ballet
Steven Ballet

8 November 2016 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JDJolanta Dyniewicz
Jolanta Dyniewicz
PLPiotr Lipiński
Piotr Lipiński
PKPiotr Kosson
Piotr Kosson
ALAnna Lesniak
Anna Lesniak
MBMarta Bochyńska-Czyż
Marta Bochyńska-Czyż
ALAndrzej W. Lipkowski
Andrzej W. Lipkowski

3 November 2015 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CBCecilia Betti
Cecilia Betti
JSJoanna Starnowska
Joanna Starnowska
JMJoanna Mika
Joanna Mika
JDJolanta Dyniewicz
Jolanta Dyniewicz
LFLukasz Frankiewicz
Lukasz Frankiewicz
Steven  BalletSteven Ballet
Steven Ballet

28 July 2020 in Molecules
Verified
Journal Article
Open access
PDF file
JDJolanta Dyniewicz
Jolanta Dyniewicz
PLPiotr Lipiński
Piotr Lipiński
PKPiotr Kosson
Piotr Kosson
MBMarta Bochyńska-Czyż
Marta Bochyńska-Czyż
JMJoanna Matalińska
Joanna Matalińska
Aleksandra MisickaAleksandra Misicka
Aleksandra Misicka
In the present contribution, we analyze the influence that C-terminal extension of short opioid peptide sequences by organic fragments has on receptor affinity, in vivo analgesic activity, and antimelanoma properties. The considered fragments were based on either N-acylhydrazone (NAH) or N′-acylhydrazide motifs combined with the 3,5-bis(trifluoromethyl)phenyl moiety. Eleven novel compounds were synthesized and subject to biological evaluation. The analyzed compounds exhibit a diversified range of affinities for the µ opioid receptor (MOR), rather low δ opioid receptor (DOR) affinities, and no appreciable neurokinin-1 receptor binding. In three out of four pairs, N-acylhydrazone-based derivatives bind MOR better than their N’-acylhydrazide counterparts. The best of the novel derivatives have similar low nanomolar MOR binding affinity as the reference opioids, such as morphine and biphalin. The obtained order of MOR affinities was compared to the results of molecular docking. In vivo, four tested compounds turned out to be relatively strong analgesics. Finally, the NAH-based analogues reduce the number of melanoma cells in cell culture, while their N′-acylhydrazide counterparts do not. The antimelanoma properties are roughly correlated to the lipophilicity of the compounds.

19 February 2020 in International Journal of Peptide Research and Therapeutics
Verified
Journal Article
Open access
PDF file
JMJoanna Matalińska
Joanna Matalińska
PLPiotr Lipiński
Piotr Lipiński
AKAgnieszka Kotlarz
Agnieszka Kotlarz
PKPiotr Kosson
Piotr Kosson
AMAdriana Muchowska
Adriana Muchowska
JDJolanta Dyniewicz
Jolanta Dyniewicz
In the present contribution we report design, synthesis and evaluation of receptor affinity, analgesic activity and cytotoxicity of a hybrid peptide, AWL3020. The peptide includes two pharmacophores, one of δ-opioid receptor (δOR) agonists and one of neurokinin-1 receptor (NK1R) antagonists. The design was motivated by the desire to obtain a compound with strong analgesic action and potential additional antiproliferative action. The compound displays high δOR affinity (IC50 = 29.5 nM). On the other hand, it has only poor affinity for the NK1R (IC50 = 70.28 μM). The substance shows good analgesic action which is however weaker than that of morphine. Regarding the effect on proliferation, the compound exhibits no pro-proliferative action in the assayed range. In higher concentrations, it has also cytotoxic activity. This effect is however not selective. The strongest effect of AWL3020 was found for melanoma MeW164 cell line (EC50 = 46.27 μM in reduction of cell numbers after a few days of incubation; EC50 = 37.78 μM in MTT assay).